Fmr LLC Editas Medicine, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Fmr LLC holds 96,403 shares of EDIT stock, worth $280,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

96,403

Previous 77,618 24.2%

Holding current value

$280,532

Previous $575,000 21.74%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.67 - $7.28 $87,725 - $136,754	18,785 Added 24.2%	96,403 $450,000
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $8,682 - $13,671	1,235 Added 1.62%	77,618 $575,000
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $56,137 - $99,790	-8,982 Reduced 10.52%	76,383 $773,000
Q3 2023 Nov 13, 2023	BUY	$6.92 - $9.31 $41,852 - $56,306	6,048 Added 7.63%	85,365 $665,000
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $158,701 - $286,210	24,953 Added 45.9%	79,317 $652,000
Q1 2023 May 11, 2023	BUY	$7.03 - $11.53 $2,474 - $4,058	352 Added 0.65%	54,364 $394,000
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $18,087 - $28,718	-2,174 Reduced 3.87%	54,012 $479,000
Q3 2022 Nov 10, 2022	BUY	$12.16 - $19.42 $176,429 - $281,764	14,509 Added 34.81%	56,186 $688,000
Q2 2022 Aug 12, 2022	SELL	$9.99 - $21.35 $54,515 - $116,506	-5,457 Reduced 11.58%	41,677 $493,000
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $649,975 - $1.28 Million	-46,163 Reduced 49.48%	47,134 $896,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $5.71 Million - $8.72 Million	-215,050 Reduced 69.74%	93,297 $2.48 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $10.1 Million - $18.7 Million	256,330 Added 492.78%	308,347 $12.7 Million
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $1.63 Million - $2.95 Million	52,017 New	52,017 $2.95 Million

Others Institutions Holding EDIT

# of Institutions

243

Shares Held

58.9M

Call Options Held

494K

Put Options Held

417K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $200M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account